ATE372784T1 - Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. - Google Patents

Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.

Info

Publication number
ATE372784T1
ATE372784T1 AT04290741T AT04290741T ATE372784T1 AT E372784 T1 ATE372784 T1 AT E372784T1 AT 04290741 T AT04290741 T AT 04290741T AT 04290741 T AT04290741 T AT 04290741T AT E372784 T1 ATE372784 T1 AT E372784T1
Authority
AT
Austria
Prior art keywords
protein
adenylatecyclase
terapeutic
fragments
recombinant proteins
Prior art date
Application number
AT04290741T
Other languages
English (en)
Inventor
Xavier-Edmond-Edouard Preville
Claude Leclerc
Daniel Ladant
Benedikt Timmerman
Original Assignee
Pasteur Institut
Bt Pharma
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Bt Pharma, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE372784T1 publication Critical patent/ATE372784T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04290741T 2004-03-18 2004-03-18 Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. ATE372784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290741A EP1576967B1 (de) 2004-03-18 2004-03-18 Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung.

Publications (1)

Publication Number Publication Date
ATE372784T1 true ATE372784T1 (de) 2007-09-15

Family

ID=34833798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04290741T ATE372784T1 (de) 2004-03-18 2004-03-18 Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.

Country Status (19)

Country Link
US (3) US8628779B2 (de)
EP (3) EP1576967B1 (de)
JP (2) JP5438897B2 (de)
KR (2) KR101495740B1 (de)
CN (1) CN1956730B (de)
AT (1) ATE372784T1 (de)
AU (1) AU2005224036B2 (de)
BR (1) BRPI0508722A (de)
CA (1) CA2559235C (de)
CY (1) CY1107042T1 (de)
DE (1) DE602004008874T2 (de)
DK (1) DK1576967T3 (de)
ES (1) ES2293178T3 (de)
MX (1) MXPA06010469A (de)
PL (1) PL1576967T3 (de)
PT (1) PT1576967E (de)
RU (1) RU2441022C2 (de)
SI (1) SI1576967T1 (de)
WO (1) WO2005089792A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
TWI423814B (zh) * 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
EP1894941A1 (de) * 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
EP2468763B1 (de) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV-Epitope als Ziel für zervikale Tumoren infiltrierende T-Zellen zur Verwendung bei Impfstoffen
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
AU2008280436A1 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
ES2655687T3 (es) * 2009-09-11 2018-02-21 Proyecto De Biomedicina Cima, S.L. Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
EP2478915A1 (de) 2011-01-24 2012-07-25 Genticel cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten
WO2012172042A1 (en) 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia
EP3533462A1 (de) * 2011-12-21 2019-09-04 Vaccibody AS Impfstoffe gegen hpv
EP2687849A1 (de) * 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung
EP2689786A1 (de) * 2012-07-23 2014-01-29 Genticel HPV/CYAA-basierte chimäre Proteine und deren Verwendungen bei der Induktion von Immunreaktionen gegen eine HPV-Infektion und HPV-induzierter Störungen
EP2690172A1 (de) * 2012-07-23 2014-01-29 Genticel CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen
WO2015018943A2 (en) * 2013-08-08 2015-02-12 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus
EP2975120A1 (de) 2014-07-17 2016-01-20 Institut Pasteur Monomeres und funktionelles Adenylatcyclase-CyaA-Toxin
WO2016077382A2 (en) 2014-11-11 2016-05-19 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
EP3037103A1 (de) 2014-12-23 2016-06-29 Genticel Immunotherapeutischer Impfstoff mit E7-Proteinen von HPV16 und HPV18 fusioniert mit CyaA zur Verwendung bei mit HIV infizierten Personen
DK3271382T3 (da) 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN109310749B (zh) * 2016-06-07 2022-09-23 德国癌症研究中心 Hpv l2肽免疫原性的改善
EP3323426A1 (de) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogen- und impfstoffzusammensetzungen zur verwendung gegen bordetella-bronchiseptica-infektion
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (de) 2016-12-27 2018-07-04 Genticel Immunogene zusammensetzung mit cyaa-abgeleitetem polypeptid, das eine th1/th17-orientierte immunreaktion fördert
JP7423554B2 (ja) * 2018-05-30 2024-01-29 ドイチェス クレブスフォルシュンクスツェントルム 予防用及び治療用の組み合わせワクチン
WO2021063917A1 (en) 2019-10-01 2021-04-08 Universiteit Gent Vaccine against chlamydia in swine
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
CA3197920A1 (en) * 2020-11-25 2022-06-02 Douglas E. Brough Human papilloma virus vaccines and uses of the same for hpv associated diseases
CN121487960A (zh) * 2023-04-30 2026-02-06 布坦坦研究院 重组蛋白、表达盒、免疫原性组合物及其用途
CN117777313B (zh) * 2024-01-11 2026-03-20 杭州斯达特生物科技有限公司 His-SUMO标签在制备重组HPV18 E7蛋白中的应用
WO2026044351A1 (en) * 2024-08-28 2026-03-05 The Council Of The Queensland Institute Of Medical Research Hpv antigenic composition and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
EP1715047A3 (de) * 1992-04-21 2008-08-27 Institut Pasteur Rekombinante Mutanten zur Induktion spezifischer Immunantworten
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1489092A1 (de) 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
ES2337694T3 (es) * 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP1894941A1 (de) 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
PL2233569T3 (pl) 2009-03-23 2015-02-27 Pasteur Institut Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki

Also Published As

Publication number Publication date
RU2441022C2 (ru) 2012-01-27
RU2006131598A (ru) 2008-04-27
US8628779B2 (en) 2014-01-14
EP1576967B1 (de) 2007-09-12
CY1107042T1 (el) 2012-09-26
US20140227308A1 (en) 2014-08-14
AU2005224036B2 (en) 2011-10-20
DE602004008874D1 (de) 2007-10-25
KR101495740B1 (ko) 2015-02-25
CA2559235C (en) 2015-06-16
SI1576967T1 (sl) 2008-02-29
JP5824474B2 (ja) 2015-11-25
EP1576967A1 (de) 2005-09-21
KR101382250B1 (ko) 2014-04-24
US9387243B2 (en) 2016-07-12
BRPI0508722A (pt) 2007-08-14
US20110171244A1 (en) 2011-07-14
PT1576967E (pt) 2007-12-03
US8637039B2 (en) 2014-01-28
EP2351580B1 (de) 2017-09-20
AU2005224036A1 (en) 2005-09-29
US20070072266A1 (en) 2007-03-29
PL1576967T3 (pl) 2008-03-31
MXPA06010469A (es) 2007-07-04
ES2293178T3 (es) 2008-03-16
JP5438897B2 (ja) 2014-03-12
JP2007533307A (ja) 2007-11-22
KR20070031889A (ko) 2007-03-20
KR20130079671A (ko) 2013-07-10
EP2351580A1 (de) 2011-08-03
CN1956730A (zh) 2007-05-02
CN1956730B (zh) 2012-04-25
WO2005089792A1 (en) 2005-09-29
DK1576967T3 (da) 2008-01-21
DE602004008874T2 (de) 2008-06-12
EP1725259B1 (de) 2018-02-21
JP2013176390A (ja) 2013-09-09
CA2559235A1 (en) 2005-09-29
EP1725259A1 (de) 2006-11-29

Similar Documents

Publication Publication Date Title
DE602004008874D1 (de) Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung.
WO2008026071A3 (en) Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
PL367831A1 (en) Recombinant tumor specific antibody and use thereof
DE602006021296D1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
AU2003267401A1 (en) Novel mhc ii associated peptides
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies
ATE450272T1 (de) Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
TW200716161A (en) Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
PL1694697T3 (pl) Zlokalizowane na powierzchni polipeptydy campylobacter jejuni
MX2007003624A (es) Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas.
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
MX2024009721A (es) Anticuerpos y fragmentos de anticuerpos y analogos especificos para sulfato de condroitina.
ATE521623T1 (de) Neues, bei prostatakrebs exprimiertes gen und verwendungsverfahren
UA97414C2 (ru) Выделенное человеческое антитело, связывающееся с gm-csf

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1576967

Country of ref document: EP

EEFA Change of the company name